Alignment Healthcare Q3 2026 earnings

ALHC · 2026-10-29 16:01 AMC ET · 8-K on SEC · 10-Q on SEC

Revenue and membership growth continued, but adjusted EBITDA margin collapsed to 1.6% and the company lowered full-year adjusted gross profit and EBITDA guidance.

Headline numbers

MetricActualYoYQoQ8-K location
Revenue$1,358.3 million+36.7%—Ex. 99.1, income statement
EPS (GAAP)-$0.04——Ex. 99.1, income statement
Net income-$8.1 million——Ex. 99.1, income statement
Adj. EBITDA$21.8 million-32.8%—Ex. 99.1, income statement
Adj. EBITDA margin1.6%-1.5 pp—Ex. 99.1, income statement

Revenue breakdown

not stated in the 8-K

Margins and costs

  • Gross margin 10.5% (prior 13.7%, change -3.2 pp)
  • Operating expenses $136.4 million (+24.0% YoY)
  • One-offs in the quarter Litigation costs $0; Gain on sale of property and equipment $0
  • Effective tax rate -0.2% (prior-year 0.1%, year-to-date 1.3%)
  • Non-GAAP bridge Adds back depreciation and amortization ($8.1 million), SG&A ($136.4 million), equity-based compensation ($17.5 million), and litigation costs ($0).

KPIs

MetricActualPrior quarterPrior yearChange
Health plan membership301,200294,100229,400+31.2% YoY
Medical benefits ratio89.5%86.3%87.1%+2.4 pp YoY

Guidance

MetricGuidePrior guideChange
Revenue (FY 2026)$5,245 million$5,225 million+20 million
Adjusted Gross Profit (FY 2026)$575 million$650 million-75 million
Adjusted EBITDA (FY 2026)$100 million$163 million-63 million

What drove it

  • Revenue story Revenue grew 36.7% year-over-year to $1.36 billion, driven by continued membership growth to 301,200 members.
  • EPS story Net loss widened to $8.1 million, driven by a 32.8% decline in Adjusted EBITDA and a negative tax rate.
  • One-off check Litigation costs were $0 in the quarter, compared to $555,000 in the prior year.

The good

  • Membership grew 31.2% year-over-year to 301,200
  • Revenue grew 36.7% year-over-year

The bad

  • Adjusted EBITDA margin collapsed to 1.6% from 5.1% a year ago
  • Adjusted EBITDA declined 32.8% year-over-year to $21.8 million
  • Net loss widened to $8.1 million

The ugly

  • Medical benefits ratio deteriorated to 89.5% due to higher costs from elevated appeals, disputes, catastrophic cases, and skilled nursing categories

Open questions

  • What specific actions are underway to address the higher medical costs and disputes?
  • How will the company achieve the new full-year adjusted EBITDA guidance of $100 million?
Full release

Earnings: ALHC — filed 2026-10-29

Alignment Healthcare, Inc. (ALHC) · Form 8-K, Item 2.02 · Filed · SEC filing

Alignment Healthcare Reports Third Quarter 2026 Results, Updates Full-Year Outlook

Reports third-quarter revenue of $

1.36 billion, representing

36.7% year-over-year growth

Grows health plan membership

31.2% year-over-year to

301,200 members

Issues fourth-quarter guidance and lowers full-year 2026 adjusted gross profit and adjusted EBITDA guidance

ORANGE, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Alignment Healthcare, Inc. (NASDAQ: ALHC), today reported financial results for its third quarter ended Sept. 30, 2026.

“Our third-quarter membership and revenue growth demonstrate continued demand for Alignment’s products and services, while medical trends ran higher than expected,” said John Kao, chairman and CEO. “We are taking a prudent approach to the fourth quarter and lowering our outlook based on current headwinds. Our revised guidance does not assume any benefit from the actions underway. We are confident we can deliver against these expectations. Our focus now is on execution and taking the steps necessary to drive more consistent performance as we scale and deliver profitable growth over the long term.”

Third Quarter 2026 Financial Highlights

All comparisons, unless otherwise noted, are to the three months ended

September 30, 2025.

Health plan membership at the end of the quarter was approximately 301,200, up 31.2% year-over-year

Total revenue was $1,358.3 million, up 36.7% year-over-year

Adjusted gross profit* was $142.2 million, up 11.6% year-over-year, and loss from operations was $3.8 million

Adjusted gross profit excludes depreciation and amortization of $8.1 million and selling, general, and administrative expenses of $136.4 million (which includes $16.0 million of equity-based compensation). Adjusted gross profit also excludes $1.5 million of equity-based compensation recorded within medical expenses

Medical benefits ratio based on adjusted gross profit was 89.5%, an increase of approximately 240 basis points year-over-year. The medical benefits ratio result reflects previously expected changes in Part D seasonality and timing of clinical investments, along with higher costs from elevated appeals and disputes and increased costs within catastrophic cases and skilled nursing categories

Adjusted EBITDA* of $21.8 million represented an adjusted EBITDA margin of 1.6% and declined 32.8% year-over-year, while net loss was $8.1 million, compared to net income of $3.7 million the year prior

* Please see “Third Quarter 2026 Non-GAAP Reconciliation Tables” below for more information on the non-GAAP financial measures reported here as supplemental information.

Outlook for Fourth Quarter and Fiscal Year 2026

Full-year health plan membership and revenue guidance was raised to reflect continued sales momentum, while adjusted gross profit and adjusted EBITDA guidance was lowered to reflect higher medical costs experienced during the third quarter.

Third Quarter 2026 Non-GAAP Reconciliation Tables

Adjusted Gross Profit

Financial statements

Income Statement

Three Months Ending December 31, 2026 (in millions)

Three Months Ending December 31, 2026 – No Less ThanTwelve Months Ending December 31, 2026 – No Less Than
Health Plan Membership305,000305,000
Revenue1,3165,245
Adjusted Gross Profit(1)104575
Adjusted EBITDA(1)-28100

Income Statement

Three Months Ended September 30, — is reconciled as follows: (in thousands)

Three Months Ended September 30, – 2026Three Months Ended September 30, – 2025Nine Months Ended September 30, – 2026Nine Months Ended September 30, – 2025
Income (loss) from operations-3,7947,68153,80925,036
Add back:
Equity-based compensation (medical expenses)1,5111,7754,8154,521
Depreciation (medical expenses)783374
Depreciation and amortization(2)8,1087,97723,80122,574
Selling, general, and administrative expenses136,373110,015388,514317,643
Total add back145,999119,775417,163344,812
Adjusted gross profit142,205127,456470,972369,848
(1)Adjusted gross profit is a non-GAAP financial measure that is presented as supplemental disclosure, that we define as income (loss) from operations before depreciation and amortization, medical equity-based compensation expense, and selling, general, and administrative expenses.Adjusted gross profit is a non-GAAP financial measure that is presented as supplemental disclosure, that we define as income (loss) from operations before depreciation and amortization, medical equity-based compensation expense, and selling, general, and administrative expenses.Adjusted gross profit is a non-GAAP financial measure that is presented as supplemental disclosure, that we define as income (loss) from operations before depreciation and amortization, medical equity-based compensation expense, and selling, general, and administrative expenses.Adjusted gross profit is a non-GAAP financial measure that is presented as supplemental disclosure, that we define as income (loss) from operations before depreciation and amortization, medical equity-based compensation expense, and selling, general, and administrative expenses.
(2)Amortization expense for the nine months ended September 30, 2025, includes $0.6 million in impairment expense related to the remeasurement of goodwill associated with one of our subsidiaries. There was no impairment expense for the three months ended September 30, 2025.Amortization expense for the nine months ended September 30, 2025, includes $0.6 million in impairment expense related to the remeasurement of goodwill associated with one of our subsidiaries. There was no impairment expense for the three months ended September 30, 2025.Amortization expense for the nine months ended September 30, 2025, includes $0.6 million in impairment expense related to the remeasurement of goodwill associated with one of our subsidiaries. There was no impairment expense for the three months ended September 30, 2025.Amortization expense for the nine months ended September 30, 2025, includes $0.6 million in impairment expense related to the remeasurement of goodwill associated with one of our subsidiaries. There was no impairment expense for the three months ended September 30, 2025.

Income Statement

Three Months Ended September 30, — is reconciled as follows: (in thousands)

Three Months Ended September 30, – 2026Three Months Ended September 30, – 2025Nine Months Ended September 30, – 2026Nine Months Ended September 30, – 2025
Net income (loss)-8,0523,72939,92410,028
Less: Net loss attributable to noncontrolling interest-254
Adjustments:
Interest expense4,2803,95012,61711,850
Depreciation and amortization(2)8,1157,98523,83422,648
Income tax expense-2221,2693,247
Equity-based compensation(3)17,48716,22749,68048,967
Litigation costs(4)5464811,608
Gain on sale of property and equipment-1-72
Adjusted EBITDA21,80832,439127,80498,530
(1)Adjusted EBITDA is a non-GAAP financial measure that is presented as supplemental disclosure, that we define as net income (loss) before interest expense, income taxes, depreciation and amortization expense, certain litigation costs, gains or losses on sale of property and equipment, and equity-based compensation expense.Adjusted EBITDA is a non-GAAP financial measure that is presented as supplemental disclosure, that we define as net income (loss) before interest expense, income taxes, depreciation and amortization expense, certain litigation costs, gains or losses on sale of property and equipment, and equity-based compensation expense.Adjusted EBITDA is a non-GAAP financial measure that is presented as supplemental disclosure, that we define as net income (loss) before interest expense, income taxes, depreciation and amortization expense, certain litigation costs, gains or losses on sale of property and equipment, and equity-based compensation expense.Adjusted EBITDA is a non-GAAP financial measure that is presented as supplemental disclosure, that we define as net income (loss) before interest expense, income taxes, depreciation and amortization expense, certain litigation costs, gains or losses on sale of property and equipment, and equity-based compensation expense.

Income Statement (in thousands, except per share amounts)

Three Months Ended September 30, – 2026Three Months Ended September 30, – 2025Nine Months Ended September 30, – 2026Nine Months Ended September 30, – 2025
Revenues:
Earned premiums1,348,256983,6813,901,4472,907,927
Other10,03410,01427,67327,988
Total revenues1,358,290993,6953,929,1202,935,915
Expenses:
Medical expenses1,217,603868,0223,462,9962,570,662
Selling, general, and administrative expenses136,373110,015388,514317,643
Depreciation and amortization8,1087,97723,80122,574
Total expenses1,362,084986,0143,875,3112,910,879
Income (loss) from operations-3,7947,68153,80925,036
Other expenses:
Interest expense4,2803,95012,61711,850
Other income, net-1-89
Total other expense4,2803,95012,61611,761
Income (loss) before income taxes-8,0743,73141,19313,275
Provision (benefit) for income taxes-2221,2693,247
Net income (loss)-8,0523,72939,92410,028
Less: Net loss attributable to noncontrolling interest-254
Net income (loss) attributable to Alignment Healthcare, Inc.-8,0523,72939,92410,282
Net income (loss) per share attributable to Alignment Healthcare, Inc.:
Basic-0.040.020.190.05
Diluted-0.040.020.190.05
Weighted-average common shares outstanding:
Basic208,556,942199,026,808207,132,468197,007,141
Diluted208,556,942208,927,980214,815,296208,439,200

Balance Sheet (in thousands, except par value and share amounts)

September 30, 2026December 31, 2025
Current Assets:
Cash and cash equivalents727,694575,817
Accounts receivable (less allowance for credit losses of $699 at September 30, 2026 and $833 at December 31, 2025)242,545253,207
Investments - current15,26028,413
Prepaid expenses and other current assets192,80894,140
Total current assets1,178,307951,577
Property and equipment, net66,43964,251
Right of use asset, net7,2067,019
Goodwill32,06032,060
Intangible assets, net4,5504,550
Other assets8,3016,329
Total assets1,296,8631,065,786
Current Liabilities:
Medical expenses payable621,746474,569
Accounts payable and accrued expenses34,56233,284
Accrued compensation32,74449,013
Total current liabilities689,052556,866

Cash Flow (in thousands)

Nine Months Ended September 30, – 2026Nine Months Ended September 30, – 2025
Operating Activities:
Net income39,92410,028
Adjustments to reconcile net income to net cash provided by operating activities:
Provision for credit loss699548
Gain on sale of property and equipment-1-72
Depreciation and amortization23,83422,648
Amortization-investment discount-478-1,041
Amortization-debt issuance costs1,7901,321
Equity-based compensation49,68048,967
Non-cash lease expense1,4391,178
Changes in operating assets and liabilities:
Accounts receivable9,963-66,451
Prepaid expenses and other current assets-98,668-84,326
Other assets-9-47
Medical expenses payable147,177239,008
Accounts payable and accrued expenses1,00411,185
Accrued compensation-16,2698,349
Lease liabilities-1,690-993
Net cash provided by operating activities158,395190,302
Investing Activities:
Purchase of investments-32,510-45,194
Sale of property and equipment75
Maturities of investments46,13557,995
Sale of business1,065
Acquisition of property and equipment-25,952-21,752
Net cash used in investing activities-12,327-7,811
Financing Activities:
Debt issuance costs-2,397-26
Proceeds from stock option exercises8,2312,771
Net cash provided by financing activities5,8342,745
Net increase in cash151,902185,236
Cash, cash equivalents and restricted cash at beginning of period577,937434,942
Cash, cash equivalents and restricted cash at end of period729,839620,178
Supplemental disclosure of cash flow information:
Cash paid for interest7,0136,740
Supplemental non-cash investing and financing activities:
Acquisition of property in accounts payable979

(1) is reconciled as follows:

Adjusted EBITDA

(1) is reconciled as follows:

Conference Call Details

The company will host a conference call at 5 p.m. EDT today to discuss these results and management’s outlook for future financial and operational performance. A live audio webcast will be available online at https://ir.alignmenthealth.com/. At the start of the conference call, participants may access the webcast at the following link: https://edge.media-server.com/mmc/p/o7dsxqqm. A replay of the call will be available via webcast for on-demand listening shortly after the completion of the call, at the same web links, and will remain available for approximately 12 months.

About Alignment Health

Alignment Health is championing a new path in senior care that empowers members to age well and live their most vibrant lives. A consumer brand name of Alignment Healthcare (NASDAQ: ALHC), Alignment Health’s mission-focused team makes high-quality, low-cost care a reality for its Medicare Advantage members every day. Based in California, the company partners with nationally recognized and trusted local providers to deliver coordinated care, powered by its customized care model, 24/7 concierge care team and purpose-built technology, AVA®. As it expands its offerings and grows its national footprint, Alignment upholds its core values of leading with a serving heart and putting the senior first. For more information, visit www.alignmenthealth.com.

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, as amended. These forward-looking statements include statements regarding our future growth and our financial outlook for the quarter and year ending Dec. 31, 2026. Forward-looking statements are subject to risks and uncertainties and are based on assumptions that may prove to be inaccurate, which could cause actual results to differ materially from those expected or implied by the forward-looking statements. Actual results may differ materially from the results predicted, and reported results should not be considered as an indication of future performance. Important risks and uncertainties that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: our ability to successfully execute our business plan and achieve anticipated operational improvements and financial results; our ability to manage changes in medical costs and healthcare utilization, and our ability to accurately estimate, price for and manage such costs and utilization; our ability to attract new members and enter new markets, including the need for certain governmental approvals; our ability to achieve and maintain a high rating for our plans on the Five Star Quality Rating System; our ability to develop and maintain satisfactory relationships with care providers that service our members; risks associated with being a government contractor, including potential federal reductions in MA funding; changes in laws and regulations applicable to our business model; risks related to our indebtedness; changes in market or industry conditions and receptivity to our technology and services; results of litigation or a security incident; and the impact of shortages of qualified personnel and related increases in our labor costs. For a detailed discussion of the risk factors that could affect our actual results, please refer to the risk factors identified in our Annual Report on Form 10-K for the year ended Dec. 31, 2025, our Quarterly Report on Form 10-Q for the quarter ended September 30, 2026 and the other periodic reports we file with the SEC. All information provided in this release and in the attachments is as of the date hereof, and we undertake no duty to update or revise this information unless required by law.

The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the consolidated balance sheets to the total above:

Non-GAAP Financial Measures

Certain of these financial measures are considered “non-GAAP” financial measures within the meaning of Item 10 of Regulation S-K promulgated by the SEC. We believe that non-GAAP financial measures provide an additional way of viewing aspects of our operations that, when viewed with the GAAP results, provide a more complete understanding of our results of operations and the factors and trends affecting our business. These non-GAAP financial measures are also used by our management to evaluate financial results and to plan and forecast future periods. However, non-GAAP financial measures should be considered as a supplement to, and not as a substitute for, or superior to, the corresponding measures calculated in accordance with GAAP. Non-GAAP financial measures used by us may differ from the non-GAAP measures used by other companies, including our competitors. To supplement our consolidated financial statements presented on a GAAP basis, we disclose the following non-GAAP measures: Medical Benefits Ratio, Adjusted EBITDA and Adjusted Gross Profit as these are performance measures that our management uses to assess our operating performance. Because these measures facilitate internal comparisons of our historical operating performance on a more consistent basis, we use these measures for business planning purposes and in evaluating acquisition opportunities.

Adjusted EBITDA

Adjusted EBITDA is a non-GAAP financial measure that we define as net income (loss) before interest expense, income taxes, depreciation and amortization expense, certain litigation costs, gains or losses on sale of property and equipment, and equity-based compensation expense.

Adjusted EBITDA should not be considered in isolation of, or as an alternative to, measures prepared in accordance with GAAP. There are a number of limitations related to the use of Adjusted EBITDA in lieu of net income (loss), which is the most directly comparable financial measure calculated in accordance with GAAP.

Our use of the term Adjusted EBITDA may vary from the use of similar terms by other companies in our industry and accordingly may not be comparable to similarly titled measures used by other companies.

Medical Benefits Ratio (MBR)

We calculate our MBR by dividing total medical expenses, excluding depreciation, and medical equity-based compensation, by total revenues in a given period.

Adjusted Gross Profit

Adjusted gross profit is a non-GAAP financial measure that we define as income (loss) from operations before depreciation and amortization, medical equity-based compensation expense, and selling, general, and administrative expenses.

Adjusted gross profit should not be considered in isolation of, or as an alternative to, measures prepared in accordance with GAAP. There are a number of limitations related to the use of adjusted gross profit in lieu of income (loss) from operations, which is the most directly comparable financial measure calculated in accordance with GAAP.

Our use of the term adjusted gross profit may vary from the use of similar terms by other companies in our industry and accordingly may not be comparable to similarly titled measures used by other companies.

Investor Contact

Harrison Zhuo hzhuo@ahcusa.com

Media Contact

Jerry Slowey publicrelations@ahcusa.com

Earlier releases

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.